ORIC
ORIC Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +11.1% ·
share flow +26.5% ·
net new positions +10.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 0 | 59.02M | $639.12M | +7 | −7 |
| Q1 2026 | 75 | +3 | 50.35M | $637.44M | +9 | −6 |
| Q4 2025 | 72 | +1 | 55.15M | $451.14M | +1 | — |
| Q3 2025 | 17 | 0 | 34.78M | $417.41M | — | — |
| Q2 2025 | 14 | +1 | 27.12M | $275.30M | +3 | −2 |
| Q1 2025 | 10 | +1 | 12.33M | $68.78M | +2 | −1 |
| Q4 2024 | 9 | -1 | 9.74M | $78.61M | — | −1 |
| Q3 2024 | 9 | 0 | 7.63M | $78.26M | +1 | −1 |
| Q2 2024 | 9 | — | 8.42M | $59.53M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 6.57M | +48.3% | $36.68M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 2.20M | +19.0% | $12.26M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 1.33M | +2.9% | $7.44M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 1.33M | +2.9% | $7.44M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.31M | +2.1% | $7.29M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.31M | +2.1% | $7.29M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 511.89K | +1305.3% | $2.86M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 178.22K | -4.4% | $994,451 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 178.22K | -4.4% | $994,451 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 76.99K | -44.9% | $429,604 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Millennium Management ✦ | 53.98K | +95.3% | $301,225 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 49.53K | New | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 49.53K | New | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 49.53K | New | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 49.53K | New | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 49.53K | New | $276,376 | 0.0% | New | 1 | SEC ↗ |
| 17 | Marshall Wace ✦ | 47.70K | New | $266,138 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $276,376 | 0.0% |
| AQR Capital Management | $276,376 | 0.0% |
| AQR Capital Management | $276,376 | 0.0% |
| AQR Capital Management | $276,376 | 0.0% |
| AQR Capital Management | $276,376 | 0.0% |
| Marshall Wace | $266,138 | 0.0% |
Exited
| Adage Capital Partners | $4.04M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 181 holders, 119.04M shares, $1.43B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.